209 related articles for article (PubMed ID: 33054052)
21. Human MLL-AF9 Overexpression Induces Aberrant Hematopoietic Expansion in Zebrafish.
Tan J; Zhao L; Wang G; Li T; Li D; Xu Q; Chen X; Shang Z; Wang J; Zhou J
Biomed Res Int; 2018; 2018():6705842. PubMed ID: 30003105
[TBL] [Abstract][Full Text] [Related]
22. PAF1 complex interactions with SETDB1 mediate promoter H3K9 methylation and transcriptional repression of
Ropa J; Saha N; Chen Z; Serio J; Chen W; Mellacheruvu D; Zhao L; Basrur V; Nesvizhskii AI; Muntean AG
Oncotarget; 2018 Apr; 9(31):22123-22136. PubMed ID: 29774127
[TBL] [Abstract][Full Text] [Related]
23. Degree of recruitment of DOT1L to MLL-AF9 defines level of H3K79 Di- and tri-methylation on target genes and transformation potential.
Kuntimaddi A; Achille NJ; Thorpe J; Lokken AA; Singh R; Hemenway CS; Adli M; Zeleznik-Le NJ; Bushweller JH
Cell Rep; 2015 May; 11(5):808-20. PubMed ID: 25921540
[TBL] [Abstract][Full Text] [Related]
24. Hypomethylation and expression of BEX2, IGSF4 and TIMP3 indicative of MLL translocations in acute myeloid leukemia.
Röhrs S; Dirks WG; Meyer C; Marschalek R; Scherr M; Slany R; Wallace A; Drexler HG; Quentmeier H
Mol Cancer; 2009 Oct; 8():86. PubMed ID: 19835597
[TBL] [Abstract][Full Text] [Related]
25. Selective DOT1L, LSD1, and HDAC Class I Inhibitors Reduce HOXA9 Expression in MLL-AF9 Rearranged Leukemia Cells, But Dysregulate the Expression of Many Histone-Modifying Enzymes.
Lillico R; Lawrence CK; Lakowski TM
J Proteome Res; 2018 Aug; 17(8):2657-2667. PubMed ID: 29972300
[TBL] [Abstract][Full Text] [Related]
26. Bahcc1 is critical for the aberrant epigenetic program in a mouse model of MLL-ENL-mediated leukemia.
Nakamura A; Masuya M; Shinmei M; Tawara I; Nosaka T; Ono R
Blood Adv; 2024 May; 8(9):2193-2206. PubMed ID: 38452334
[TBL] [Abstract][Full Text] [Related]
27. ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia.
Zhu L; Li Q; Wong SH; Huang M; Klein BJ; Shen J; Ikenouye L; Onishi M; Schneidawind D; Buechele C; Hansen L; Duque-Afonso J; Zhu F; Martin GM; Gozani O; Majeti R; Kutateladze TG; Cleary ML
Cancer Discov; 2016 Jul; 6(7):770-83. PubMed ID: 27154821
[TBL] [Abstract][Full Text] [Related]
28. Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes.
Chang MJ; Wu H; Achille NJ; Reisenauer MR; Chou CW; Zeleznik-Le NJ; Hemenway CS; Zhang W
Cancer Res; 2010 Dec; 70(24):10234-42. PubMed ID: 21159644
[TBL] [Abstract][Full Text] [Related]
29. ZNF521 Enhances MLL-AF9-Dependent Hematopoietic Stem Cell Transformation in Acute Myeloid Leukemias by Altering the Gene Expression Landscape.
Chiarella E; Aloisio A; Scicchitano S; Todoerti K; Cosentino EG; Lico D; Neri A; Amodio N; Bond HM; Mesuraca M
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639154
[TBL] [Abstract][Full Text] [Related]
30. Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications.
Milne TA; Martin ME; Brock HW; Slany RK; Hess JL
Cancer Res; 2005 Dec; 65(24):11367-74. PubMed ID: 16357144
[TBL] [Abstract][Full Text] [Related]
31. Regulation of HOXA9 activity by predominant expression of DACH1 against C/EBPα and GATA-1 in myeloid leukemia with MLL-AF9.
Lee JW; Kim HS; Hwang J; Kim YH; Lim GY; Sohn WJ; Yoon SR; Kim JY; Park TS; Oh SH; Park KM; Choi SU; Ryoo ZY; Lee S
Biochem Biophys Res Commun; 2012 Sep; 426(3):299-305. PubMed ID: 22902925
[TBL] [Abstract][Full Text] [Related]
32. The stem cell factor SALL4 is an essential transcriptional regulator in mixed lineage leukemia-rearranged leukemogenesis.
Yang L; Liu L; Gao H; Pinnamaneni JP; Sanagasetti D; Singh VP; Wang K; Mathison M; Zhang Q; Chen F; Mo Q; Rosengart T; Yang J
J Hematol Oncol; 2017 Oct; 10(1):159. PubMed ID: 28974232
[TBL] [Abstract][Full Text] [Related]
33. Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes.
Biswas D; Milne TA; Basrur V; Kim J; Elenitoba-Johnson KS; Allis CD; Roeder RG
Proc Natl Acad Sci U S A; 2011 Sep; 108(38):15751-6. PubMed ID: 21896721
[TBL] [Abstract][Full Text] [Related]
34. EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs.
Bindels EM; Havermans M; Lugthart S; Erpelinck C; Wocjtowicz E; Krivtsov AV; Rombouts E; Armstrong SA; Taskesen E; Haanstra JR; Beverloo HB; Döhner H; Hudson WA; Kersey JH; Delwel R; Kumar AR
Blood; 2012 Jun; 119(24):5838-49. PubMed ID: 22553314
[TBL] [Abstract][Full Text] [Related]
35. H3K79 methylation profiles define murine and human MLL-AF4 leukemias.
Krivtsov AV; Feng Z; Lemieux ME; Faber J; Vempati S; Sinha AU; Xia X; Jesneck J; Bracken AP; Silverman LB; Kutok JL; Kung AL; Armstrong SA
Cancer Cell; 2008 Nov; 14(5):355-68. PubMed ID: 18977325
[TBL] [Abstract][Full Text] [Related]
36. Leukemic transformation of hematopoietic progenitors by MLL-GAS7 in the absence of Hoxa7 or Hoxa9.
So CW; Karsunky H; Wong P; Weissman IL; Cleary ML
Blood; 2004 Apr; 103(8):3192-9. PubMed ID: 15070702
[TBL] [Abstract][Full Text] [Related]
37. hDOT1L links histone methylation to leukemogenesis.
Okada Y; Feng Q; Lin Y; Jiang Q; Li Y; Coffield VM; Su L; Xu G; Zhang Y
Cell; 2005 Apr; 121(2):167-78. PubMed ID: 15851025
[TBL] [Abstract][Full Text] [Related]
38. The trithorax protein partner menin acts in tandem with EZH2 to suppress C/EBPα and differentiation in MLL-AF9 leukemia.
Thiel AT; Feng Z; Pant DK; Chodosh LA; Hua X
Haematologica; 2013 Jun; 98(6):918-27. PubMed ID: 23349306
[TBL] [Abstract][Full Text] [Related]
39. Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations.
Dorrance AM; Liu S; Yuan W; Becknell B; Arnoczky KJ; Guimond M; Strout MP; Feng L; Nakamura T; Yu L; Rush LJ; Weinstein M; Leone G; Wu L; Ferketich A; Whitman SP; Marcucci G; Caligiuri MA
J Clin Invest; 2006 Oct; 116(10):2707-16. PubMed ID: 16981007
[TBL] [Abstract][Full Text] [Related]
40. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.
Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW
Cancer Res; 2016 Mar; 76(5):1158-69. PubMed ID: 26627013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
